Evanston Township High School approves $2.5 million Arts, Innovation Wing expansion
The board approved awarding $2.5 million in construction contracts for the first phase of renovations and upgrades to the Arts & Innovation wing. Construction is scheduled to begin over the summer.
The renovations to the Arts & Innovation space include a new orchestra space, a black box style theater and an extended hallway for the first phase of approved bids.
Bulley and Andrews, a Chicago-based construction group, is overseeing the bidding process and construction. In a letter from Bulley and Andrews' Senior Project Manager Antonia Winfrey to the district's Chief Financial Officer Kendra Williams, Winfrey recommended that the board approve 11 bids for the first phase of construction.
Winfrey recommended an additional five bids for general trades, wood flooring, drywall, electric and excavation go out to bid again to ensure a fair and competitive bidding process and for the project to keep on schedule.
Per the letter, the district has chosen to postpone accepting further bids for an orchestra addition, seating for the theater, a hallway extension and portable recording equipment before the May Board of Education meeting.
Construction for the expansion and other upgrades to ETHS are being funded through the Evanston Township High School Education Foundation.
Throughout the school year, ETHS has been celebrating the 100 year anniversary of its move to its current location near Church Street and Dodge Avenue in Evanston.
The foundation has solicited and received big donations in the last year. In January, the Board of Education approved a $7 million gift, to be paid in installments, from an alumnus, Leonard Schaeffer, to upgrade the high school's auditorium.
And in February, the board approved a $2.5 million donation from the Lewis-Sebring Family Foundation to upgrade the school's facilities, infrastructure and learning spaces.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
The Braff Group Advises IV Solutions, LLC in its Sale to Singlepoint Healthcare
PITTSBURGH, Aug. 14, 2025 /PRNewswire/ -- Singlepoint Healthcare, a portfolio of DFW Capital Partners announced last week the acquisition of IV Solutions, LLC (IVS), a leading provider of clinical pharmacy and home infusion services in Wood Dale, Ill. This acquisition helps establish a strong foundation for Singlepoint's integrated model and provide access to critical expertise in both clinical care and pharmaceutical services. The Braff Group served as the exclusive financial advisor for IV Solutions, LLC. Singlepoint is backed by DFW Capital Partners, a New York-based investor focused on partnering with growth-oriented healthcare and business services companies. The firm works alongside experienced management teams to accelerate expansion, enhance operations and build durable, scalable platforms that deliver long-term value. The company's initial platform includes The Boster Center for Multiple Sclerosis and IV Solutions. "IVS fit seamlessly into the Singlepoint Health multi-specialty network and allowed for the immediate growth of the Singlepoint model," commented Pat Clifford, The Braff Group Managing Director that headed up the deal team representing IV Solutions, LLC. About The Braff Group: Founded in 1998, The Braff Group is the leading health care advisory firm specializing exclusively in behavioral health, home health, home care and hospice, health care staffing, home medical equipment and pharmacy services. The firm has completed over 385 transactions and has been repeatedly ranked among the top five health care mergers and acquisitions advisory firms. Visit and follow The Braff Group on LinkedIn. Contact: Karen Cullen kcullen@ View original content to download multimedia: SOURCE The Braff Group Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Forbes
an hour ago
- Forbes
Lions, Commanders, Bears Ticket Sales Spike Ahead Of 2025 Season
Ticket sales for the Detroit Lions, Washington Commanders and Chicago Bears show the biggest surge in price heading into the 2025 season when compared to last year, new data from ticket reseller Vivid Seats shows. Dylan Drummond of the Atlanta Falcons makes a reception and is tackled by Avonte Maddox #of the Detroit Lions during an NFL Preseason 2025 game Aug. 8, 2025. Getty Images Surging demand has driven up ticket prices for the Lions home and away games by 29% year over year on the platform, and prices are up 24% for the Commanders and 21% for the Bears. The Philadelphia Eagles and Minnesota Vikings also show increased demand, with a 17% and 16% increase in ticket prices from last year, respectively. Vivid Seats data show the Dallas Cowboys are the team with the most widespread fans, in 290 counties, more than any other team, followed by the Kansas City Chiefs (262 counties) and the Vikings (207 counties). When it comes to the most dedicated fans, the Eagles and Las Vegas Raiders lead—the Eagles have the most fans at away games, filling 47% of seats, and Raiders fans are willing to travel the furthest to see a game, averaging 575 miles per game last season. The NFC is the conference leading the market in demand for re-sale tickets, the Vivid Seats data shows, with an average sale price of $331, topping the AFC's $297. Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text 'Alerts' to (201) 335-0739 or sign up here : The Detroit Lions have seen a surge in popularity and fan engagement in recent years as the team rises in the rankings. The "Honolulu Blue wave" phenomenon, a reference to the team's signature color, has seen a surge in jersey sales, heightened social media activity and now a boost in ticket interest. The 2024-2025 season was the best in franchise history with an ending record of 15-2, a franchise record for wins, and saw them secure the NFC's No. 1 seed and a first-round bye. The Lions also had their best start since 1934. Going into the 2025 season, the Lions are the No. 2 seed in the NFC North. $131.82. That was the average NFL ticket price last regular season, up 9% from $120.94 the season before. What To Watch For If NFL sees a boost in broadcast viewers, too. The start of the 2024 season brought a viewership surge that shot the league to a nine-year high in television ratings, averaging 18.6 million viewers across the first three weeks. The viewership number was a significant boost from 2023's season's average of 17.9 million, which was itself the highest since 2015. The surge was attributed largely to the "Taylor Swift effect"—interest in her relationship with Kansas City Chiefs tight end Travis Kelce—bringing an influx of women and girls to the sport. The "Swift bump" increased viewership, jersey sales, and social media engagement. Other factors credited with contributing to the surge include the league's efforts to boost fan engagement, like licensing games to streaming services, the rise of sports betting and more participation in fantasy football. Further Reading Forbes The NFL's Most Valuable Teams 2024 By Justin Teitelbaum Forbes NFL Preseason Has New Meaning For Bengals, Colts, Jags, Vikings By Steve Silverman Forbes How To Play Fantasy Football (Guide For Beginners) By Steve Bradshaw
